Related Experiment Videos
Effect of acidic and basic isoferritins on in vitro growth of human granulocyte-monocyte progenitors
Abstract:
Acidic isoferritins have been previously found to be highly potent inhibitors of hematopoietic progenitors at concentrations of 10(-16) to 10(-18) mol/L, and it has been suggested that acidic isoferritin inhibitory activity plays a role in the regulation of normal hematopoiesis and also in the pathogenesis of leukemia. To characterize the ferritin species that affect the in vitro growth of human colony-forming unit-granulocyte-macrophage (CFU-GM), we tested different preparations of basic (L-subunit-rich) and acidic (H-subunit-rich) isoferritins. Three preparations of human liver (basic) ferritin did not show any effects on CFU-GM growth at concentrations up to 10(-9) mol/L, irrespective of the degree of glycosylation. Acidic isoferritins were purified both from HeLa cells and human heart. HeLa cell ferritin did not affect in vitro colony formation. One of two preparations of human heart ferritin, containing 5% glycosylated ferritin, showed a mean inhibition of 26% +/- 8% of the control at 10(-9) mol/L (P less than .02), whereas the other preparation, which contained no glycosylated ferritin, did not show any effect of CFU-GM growth. A preparation enriched for glycosylated acidic isoferritins from human heart was found to produce a mean inhibition of 32% +/- 11% of the control at 10(-9) mol/L (P less than .01), whereas another one was ineffective. A significant part of the inhibitory activity was removed by preincubation with the monoclonal antibody 2A4 directed against human heart ferritin. The present findings indicate that basic isoferritins, ie, the predominant ferritin type in human blood, have no effect on the growth of human CFU-GM, and this is in keeping with indirect clinical evidence. Inhibition of colony formation may be obtained by some preparations of acidic isoferritins that are rich in H subunits and bind to concanavalin A. The mechanism(s) responsible for this are not clear, but the effective concentrations are higher than those found in human blood both under normal conditions and in leukemia. At present, the physiologic significance of the observed inhibitory activity is uncertain.
Insights
Acidic isoferritins, particularly glycosylated forms from human heart, can inhibit hematopoietic progenitor growth. However, basic isoferritins do not affect this process, and effective concentrations exceed physiological levels.
Area of Science:
- Hematology
- Cell Biology
- Biochemistry
Background:
- Acidic isoferritins are implicated as potent inhibitors of hematopoietic progenitors.
- Previous research suggests a role for acidic isoferritin activity in normal hematopoiesis and leukemia pathogenesis.
- Understanding ferritin species' effects on human colony-forming unit-granulocyte-macrophage (CFU-GM) growth is crucial.
Purpose of the Study:
- To characterize ferritin species influencing in vitro human CFU-GM growth.
- To differentiate the effects of basic (L-subunit-rich) and acidic (H-subunit-rich) isoferritins.
Main Methods:
- Tested preparations of basic (liver) and acidic (HeLa, heart) isoferritins on human CFU-GM.
- Assessed effects of glycosylation and used monoclonal antibody 2A4 against human heart ferritin.
- Measured inhibition of colony formation at specific isoferritin concentrations (up to 10(-9) mol/L).
Main Results:
- Basic human liver ferritin showed no effect on CFU-GM growth.
- Acidic isoferritins from HeLa cells were ineffective.
- Certain preparations of acidic human heart ferritin, especially glycosylated forms, exhibited significant inhibitory activity (26-32%) on CFU-GM growth at 10(-9) mol/L.
- Inhibitory activity was partially neutralized by antibody 2A4, suggesting a role for human heart ferritin.
Conclusions:
- Basic isoferritins do not inhibit human CFU-GM growth.
- Specific acidic isoferritin preparations, rich in H subunits and potentially glycosylated, can inhibit CFU-GM.
- Observed inhibitory concentrations are higher than physiological levels, questioning the current clinical significance.